Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
308.2 USD | +0.65% | +4.98% | +19.32% |
Apr. 26 | Morgan Stanley Raises Price Target on Axon Enterprise to $310 From $285 | MT |
Apr. 23 | Raymond James Raises Axon Enterprise Price Target to $330 from $300 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 120.11 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Aerospace & Defense
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.32% | 23.26B | C- | ||
+20.53% | 135B | C | ||
+9.53% | 77.91B | B | ||
+2.63% | 71.1B | A- | ||
+20.67% | 50.29B | B | ||
+40.51% | 43.87B | A- | ||
+1.86% | 40.78B | B+ | ||
+42.10% | 31.95B | C- | ||
+29.77% | 20.94B | B- | ||
+45.70% | 13.36B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AXON Stock
- Ratings Axon Enterprise, Inc.